Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
GlobeNewswire
· Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week..